{"product_id":"cleveland-clinic-the-new-age-of-alzheimers-disease-therapeutics-2025","title":"Cleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eCleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 5 videos + 5 audios + 5 fle sub vtt + 1 pdf, size: 2 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: neurologists, primary care physicians, internists, geriatricians\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThe introduction of anti-amyloid therapies as a new class of treatment for Alzheimer’s Disease (AD) has brought significant advances in the care of patients with mild cognitive impairment (MCI) and early-stage AD. However, healthcare providers, especially neurologists, face numerous challenges in integrating these therapies into clinical practice. These include uncertainties regarding patient selection, pre-authorization and insurance processes, infusion logistics, management of potential side effects like ARIA (amyloid-related imaging abnormalities), and determining the appropriate duration and frequency of treatment.\u003cbr\u003e\u003cbr\u003eThe goal of this program is to provide healthcare professionals with the necessary tools, knowledge, and resources to confidently navigate these challenges. The conference will address critical aspects of anti-amyloid therapies in clinical practice, including cognitive assessment, patient selection, the pre-authorization process, infusion logistics, and the management of side effects like ARIA.\u003cbr\u003e\u003cbr\u003eThis conference will also foster greater collaboration between neurologists and primary care physicians (PCPs), enabling early recognition and screening for AD and MCI, ultimately improving patient outcomes by accelerating the anti-amyloid treatment process.\u003cbr\u003e\u003ch3\u003eTARGET AUDIENCE\u003c\/h3\u003e\n\u003cbr\u003eThis activity is designed for neurologists, primary care physicians (PCPs), internists, geriatricians, nurse practitioners, nurses, and other healthcare providers involved in the diagnosis, management, and treatment of patients with Alzheimer’s Disease or MCI.\u003cbr\u003e\u003ch3\u003eLEARNING OBJECTIVES\u003c\/h3\u003e\n\u003cbr\u003eUpon completion of this program, participants will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDescribe the clinical effects of anti-amyloid therapies and be able to convey to patients.\u003c\/li\u003e\n\u003cli\u003eIdentify patients that are candidates for anti-amyloid therapies.\u003c\/li\u003e\n\u003cli\u003eRecognize and monitor the potential complications of anti-amyloid therapies.\u003c\/li\u003e\n\u003cli\u003eList the administrative steps necessary to prescribe anti-amyloid therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e01 Background on antiamyloid therapies Charles Bernick, MD, MPH\u003c\/li\u003e\n\u003cli\u003e02 Translating clinical trial results to the clinic Babak Tousi, MD\u003c\/li\u003e\n\u003cli\u003e03 Who is the right patient for anti-amyloid therapies Lakeshia Gibson, MD\u003c\/li\u003e\n\u003cli\u003e04 Surveillance for amyloid-related imaging abnormalities (ARIA) Dylan Wint, MD\u003c\/li\u003e\n\u003cli\u003e05 Logistics of starting anti-amyloid therapy Maileen Ulep, PhD, MSN, APRN, FNP-BC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954538254434,"sku":"MED-AMB05609","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Cleveland-Clinic-The-New-Age-of-Alzheimers-Disease-Therapeutics-2025.jpg?v=1779379260","url":"https:\/\/meducourse.com\/products\/cleveland-clinic-the-new-age-of-alzheimers-disease-therapeutics-2025","provider":"Meducourse","version":"1.0","type":"link"}